- Raised $150k funding round, Jun 2023
About
Nano Painkiller offers Focus Pain Ablation (FPA) technology as a groundbreaking, non-drug solution for targeted, permanent chronic pain relief. This innovation addresses the massive global health and economic burden of chronic pain, which affects approximately 20% of the adult Western population and fuels a global drug market valued at $78.41 billion in 2022. The critical need for alternatives stems from the opioid crisis, which has resulted in addiction, overdoses, and deaths, highlighting the failures and risks of current systemic drug therapies.
The core technology uses a molecule comprising Gold Nanoparticles (AuNP), conjugated with a neuronal tracer. This molecule is injected into the painful area and transported retrogradely along the nerve axon to the sensory nerve cell body located in the Dorsal Root Ganglion (DRG). External Ultrasound (US) energy is then applied to the DRG to activate the nanoparticles, causing localized destruction of the specific cell body and silencing the pain signal. This two-stage selectivity ensures that motor nerves are not affected.
The primary business opportunity lies in replacing repeat-intensive procedures and long-term drug dependence with a permanent solution. The initial application targets Knee Osteoarthritis Pain, a condition affecting 300 million people worldwide and valued at $6.76 billion. Compared to current Radiofrequency Ablation (RFA), FPA offers a longer-lasting effect because ablating the DRG cell body prevents nerve regrowth, thereby eliminating the need for repeating treatment every 3–6 months.
Funding history · 1 round · $150K total
Q&A
- What is Exodus Technology's primary focus?
- Exodus Technology, formerly Nano Paikiller, focuses on developing a nanoparticle-based, non-drug solution for targeted, permanent chronic pain relief, specifically using Focus Pain Ablation (FPA) technology.
- When was Exodus Technology founded?
- Exodus Technology was founded in January 2023.
- What is the core technology behind Exodus Technology's solution?
- The core technology uses a molecule comprising Gold Nanoparticles (AuNP) conjugated with a neuronal tracer. This molecule is injected into the painful area, transported to the Dorsal Root Ganglion (DRG), and then activated by external Ultrasound energy to destroy specific cell bodies and silence pain signals.
- Which medical condition is Exodus Technology initially targeting?
- Exodus Technology's initial application targets Knee Osteoarthritis Pain.
- How much funding has Exodus Technology raised to date?
- Exodus Technology has raised a total of $150,000.
- When was Exodus Technology's last funding round, and who participated?
- Exodus Technology's last funding round occurred in June 2023, with participation from Israel Innovation Authority.
- What is Exodus Technology's current employee count?
- Exodus Technology has 1-10 employees.
- Who is the CEO of Exodus Technology?
- Michael Zilbershlag is the CEO and a founder of Exodus Technology.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | nano-pk.com |
|---|
Identifiers & details
| Former names | Nano Paikiller |
|---|---|
| Founded | 2023-1 |
| Employees (exact) | 3 |
Radar intelligence
Web history (Wayback)
| Domain | nano-pk.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|